LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000329

Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors

Identifieur interne : 000329 ( PascalFrancis/Corpus ); précédent : 000328; suivant : 000330

Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors

Auteurs : Kathryn H. Schmitz ; Andrea B. Troxel ; Andrea Cheville ; Lorita L. Grant ; Cathy J. Bryan ; Cynthia R. Gross ; Leslie A. Lytle ; Rehana L. Ahmed

Source :

Contemporary clinical trials [ 1551-7144 ] ; 2009.

RBID : Pascal:09-0268266

Descripteurs français

Pascal (Inist)
- Exercice physique, Lymphoedème, Essai clinique, Toxicité, Sécurité, Résistance mécanique, Cancer du sein, Homme, Survivant, Méthodologie, Evaluation performance, Analyse statistique, Protocole expérimental.

English descriptors

KwdEn :
- Breast cancer, Clinical trial, Experimental protocol, Human, Lymphedema, Methodology, Performance evaluation, Physical exercise, Safety, Statistical analysis, Strength, Survivor, Toxicity.

Abstract

Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1551-7144`
A03		`1`		`@0 contemp. clin. trials`
A05				`@2 30`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors`
A11	`01`	`1`		`@1 SCHMITZ (Kathryn H.)`
A11	`02`	`1`		`@1 TROXEL (Andrea B.)`
A11	`03`	`1`		`@1 CHEVILLE (Andrea)`
A11	`04`	`1`		`@1 GRANT (Lorita L.)`
A11	`05`	`1`		`@1 BRYAN (Cathy J.)`
A11	`06`	`1`		`@1 GROSS (Cynthia R.)`
A11	`07`	`1`		`@1 LYTLE (Leslie A.)`
A11	`08`	`1`		`@1 AHMED (Rehana L.)`
A14	`01`			`@1 University of Pennsylvania School of Medicine @2 Philadelphia, PA @3 USA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut.`
A14	`02`			`@1 Mayo Clinic @2 Rochester, MN @3 USA @Z 3 aut.`
A14	`03`			`@1 University of Minnesota @2 Minneapolis, MN @3 USA @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A20				`@1 233-245`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18357 @5 354000188266940070`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 107 ref.`
A47	`01`	`1`		`@0 09-0268266`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Contemporary clinical trials`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.
C02	`01`	`X`		`@0 002B12B04`
C02	`02`	`X`		`@0 002B20E02`
C02	`03`	`X`		`@0 002B02A06`
C03	`01`	`X`	`FRE`	`@0 Exercice physique @5 01`
C03	`01`	`X`	`ENG`	`@0 Physical exercise @5 01`
C03	`01`	`X`	`SPA`	`@0 Ejercicio físico @5 01`
C03	`02`	`X`	`FRE`	`@0 Lymphoedème @5 02`
C03	`02`	`X`	`ENG`	`@0 Lymphedema @5 02`
C03	`02`	`X`	`SPA`	`@0 Linfedema @5 02`
C03	`03`	`X`	`FRE`	`@0 Essai clinique @5 03`
C03	`03`	`X`	`ENG`	`@0 Clinical trial @5 03`
C03	`03`	`X`	`SPA`	`@0 Ensayo clínico @5 03`
C03	`04`	`X`	`FRE`	`@0 Toxicité @5 04`
C03	`04`	`X`	`ENG`	`@0 Toxicity @5 04`
C03	`04`	`X`	`SPA`	`@0 Toxicidad @5 04`
C03	`05`	`X`	`FRE`	`@0 Sécurité @5 05`
C03	`05`	`X`	`ENG`	`@0 Safety @5 05`
C03	`05`	`X`	`SPA`	`@0 Seguridad @5 05`
C03	`06`	`X`	`FRE`	`@0 Résistance mécanique @5 06`
C03	`06`	`X`	`ENG`	`@0 Strength @5 06`
C03	`06`	`X`	`SPA`	`@0 Resistencia mecánica @5 06`
C03	`07`	`X`	`FRE`	`@0 Cancer du sein @2 NM @5 07`
C03	`07`	`X`	`ENG`	`@0 Breast cancer @2 NM @5 07`
C03	`07`	`X`	`SPA`	`@0 Cáncer del pecho @2 NM @5 07`
C03	`08`	`X`	`FRE`	`@0 Homme @5 08`
C03	`08`	`X`	`ENG`	`@0 Human @5 08`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 08`
C03	`09`	`X`	`FRE`	`@0 Survivant @5 09`
C03	`09`	`X`	`ENG`	`@0 Survivor @5 09`
C03	`09`	`X`	`SPA`	`@0 Sobreviviente @5 09`
C03	`10`	`X`	`FRE`	`@0 Méthodologie @5 10`
C03	`10`	`X`	`ENG`	`@0 Methodology @5 10`
C03	`10`	`X`	`SPA`	`@0 Metodología @5 10`
C03	`11`	`X`	`FRE`	`@0 Evaluation performance @5 11`
C03	`11`	`X`	`ENG`	`@0 Performance evaluation @5 11`
C03	`11`	`X`	`SPA`	`@0 Evaluación prestación @5 11`
C03	`12`	`X`	`FRE`	`@0 Analyse statistique @5 12`
C03	`12`	`X`	`ENG`	`@0 Statistical analysis @5 12`
C03	`12`	`X`	`SPA`	`@0 Análisis estadístico @5 12`
C03	`13`	`X`	`FRE`	`@0 Protocole expérimental @5 13`
C03	`13`	`X`	`ENG`	`@0 Experimental protocol @5 13`
C03	`13`	`X`	`SPA`	`@0 Protocolo experimental @5 13`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie des vaisseaux lymphatiques @5 38`
C07	`02`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 39`
C07	`04`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`04`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`04`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la glande mammaire @2 NM @5 40`
C07	`05`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 40`
C07	`05`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie du sein @2 NM @5 41`
C07	`06`	`X`	`ENG`	`@0 Breast disease @2 NM @5 41`
C07	`06`	`X`	`SPA`	`@0 Seno patología @2 NM @5 41`
N21				`@1 195`

Format Inist (serveur)

NO :	PASCAL 09-0268266 INIST
ET :	Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors
AU :	SCHMITZ (Kathryn H.); TROXEL (Andrea B.); CHEVILLE (Andrea); GRANT (Lorita L.); BRYAN (Cathy J.); GROSS (Cynthia R.); LYTLE (Leslie A.); AHMED (Rehana L.)
AF :	University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (1 aut., 2 aut., 4 aut., 5 aut.); Mayo Clinic/Rochester, MN/Etats-Unis (3 aut.); University of Minnesota/Minneapolis, MN/Etats-Unis (6 aut., 7 aut., 8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Contemporary clinical trials; ISSN 1551-7144; Etats-Unis; Da. 2009; Vol. 30; No. 3; Pp. 233-245; Bibl. 107 ref.
LA :	Anglais
EA :	Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.
CC :	002B12B04; 002B20E02; 002B02A06
FD :	Exercice physique; Lymphoedème; Essai clinique; Toxicité; Sécurité; Résistance mécanique; Cancer du sein; Homme; Survivant; Méthodologie; Evaluation performance; Analyse statistique; Protocole expérimental
FG :	Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein
ED :	Physical exercise; Lymphedema; Clinical trial; Toxicity; Safety; Strength; Breast cancer; Human; Survivor; Methodology; Performance evaluation; Statistical analysis; Experimental protocol
EG :	Cardiovascular disease; Lymphatic vessel disease; Malignant tumor; Cancer; Mammary gland diseases; Breast disease
SD :	Ejercicio físico; Linfedema; Ensayo clínico; Toxicidad; Seguridad; Resistencia mecánica; Cáncer del pecho; Hombre; Sobreviviente; Metodología; Evaluación prestación; Análisis estadístico; Protocolo experimental
LO :	INIST-18357.354000188266940070
ID :	09-0268266

Links to Exploration step

Pascal:09-0268266

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors</title>
<author><name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H." last="Schmitz">Kathryn H. Schmitz</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Troxel, Andrea B" sort="Troxel, Andrea B" uniqKey="Troxel A" first="Andrea B." last="Troxel">Andrea B. Troxel</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cheville, Andrea" sort="Cheville, Andrea" uniqKey="Cheville A" first="Andrea" last="Cheville">Andrea Cheville</name>
<affiliation><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grant, Lorita L" sort="Grant, Lorita L" uniqKey="Grant L" first="Lorita L." last="Grant">Lorita L. Grant</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bryan, Cathy J" sort="Bryan, Cathy J" uniqKey="Bryan C" first="Cathy J." last="Bryan">Cathy J. Bryan</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gross, Cynthia R" sort="Gross, Cynthia R" uniqKey="Gross C" first="Cynthia R." last="Gross">Cynthia R. Gross</name>
<affiliation><inist:fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lytle, Leslie A" sort="Lytle, Leslie A" uniqKey="Lytle L" first="Leslie A." last="Lytle">Leslie A. Lytle</name>
<affiliation><inist:fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ahmed, Rehana L" sort="Ahmed, Rehana L" uniqKey="Ahmed R" first="Rehana L." last="Ahmed">Rehana L. Ahmed</name>
<affiliation><inist:fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0268266</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0268266 INIST</idno>
<idno type="RBID">Pascal:09-0268266</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000329</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors</title>
<author><name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H." last="Schmitz">Kathryn H. Schmitz</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Troxel, Andrea B" sort="Troxel, Andrea B" uniqKey="Troxel A" first="Andrea B." last="Troxel">Andrea B. Troxel</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cheville, Andrea" sort="Cheville, Andrea" uniqKey="Cheville A" first="Andrea" last="Cheville">Andrea Cheville</name>
<affiliation><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grant, Lorita L" sort="Grant, Lorita L" uniqKey="Grant L" first="Lorita L." last="Grant">Lorita L. Grant</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bryan, Cathy J" sort="Bryan, Cathy J" uniqKey="Bryan C" first="Cathy J." last="Bryan">Cathy J. Bryan</name>
<affiliation><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gross, Cynthia R" sort="Gross, Cynthia R" uniqKey="Gross C" first="Cynthia R." last="Gross">Cynthia R. Gross</name>
<affiliation><inist:fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lytle, Leslie A" sort="Lytle, Leslie A" uniqKey="Lytle L" first="Leslie A." last="Lytle">Leslie A. Lytle</name>
<affiliation><inist:fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ahmed, Rehana L" sort="Ahmed, Rehana L" uniqKey="Ahmed R" first="Rehana L." last="Ahmed">Rehana L. Ahmed</name>
<affiliation><inist:fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Contemporary clinical trials</title>
<title level="j" type="abbreviated">contemp. clin. trials</title>
<idno type="ISSN">1551-7144</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Contemporary clinical trials</title>
<title level="j" type="abbreviated">contemp. clin. trials</title>
<idno type="ISSN">1551-7144</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast cancer</term>
<term>Clinical trial</term>
<term>Experimental protocol</term>
<term>Human</term>
<term>Lymphedema</term>
<term>Methodology</term>
<term>Performance evaluation</term>
<term>Physical exercise</term>
<term>Safety</term>
<term>Statistical analysis</term>
<term>Strength</term>
<term>Survivor</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Exercice physique</term>
<term>Lymphoedème</term>
<term>Essai clinique</term>
<term>Toxicité</term>
<term>Sécurité</term>
<term>Résistance mécanique</term>
<term>Cancer du sein</term>
<term>Homme</term>
<term>Survivant</term>
<term>Méthodologie</term>
<term>Evaluation performance</term>
<term>Analyse statistique</term>
<term>Protocole expérimental</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1551-7144</s0>
</fA01>
<fA03 i2="1"><s0>contemp. clin. trials</s0>
</fA03>
<fA05><s2>30</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHMITZ (Kathryn H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TROXEL (Andrea B.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHEVILLE (Andrea)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GRANT (Lorita L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BRYAN (Cathy J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GROSS (Cynthia R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LYTLE (Leslie A.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>AHMED (Rehana L.)</s1>
</fA11>
<fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Minnesota</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>233-245</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18357</s2>
<s5>354000188266940070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>107 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0268266</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Contemporary clinical trials</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02A06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Exercice physique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Physical exercise</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Ejercicio físico</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Sécurité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Safety</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Seguridad</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Résistance mécanique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Strength</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Resistencia mecánica</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Survivant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Survivor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Sobreviviente</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Méthodologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Methodology</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Metodología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Evaluation performance</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Performance evaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Evaluación prestación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Analyse statistique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Statistical analysis</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Análisis estadístico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Protocole expérimental</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Experimental protocol</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Protocolo experimental</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fN21><s1>195</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 09-0268266 INIST</NO>
<ET>Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors</ET>
<AU>SCHMITZ (Kathryn H.); TROXEL (Andrea B.); CHEVILLE (Andrea); GRANT (Lorita L.); BRYAN (Cathy J.); GROSS (Cynthia R.); LYTLE (Leslie A.); AHMED (Rehana L.)</AU>
<AF>University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (1 aut., 2 aut., 4 aut., 5 aut.); Mayo Clinic/Rochester, MN/Etats-Unis (3 aut.); University of Minnesota/Minneapolis, MN/Etats-Unis (6 aut., 7 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Contemporary clinical trials; ISSN 1551-7144; Etats-Unis; Da. 2009; Vol. 30; No. 3; Pp. 233-245; Bibl. 107 ref.</SO>
<LA>Anglais</LA>
<EA>Lymphedema is a chronic and progressive long-term adverse effect of breast cancer treatment commonly defined by swelling of the affected arm. Current clinical guidelines indicate that women with and at risk for lymphedema should protect the affected arm from overuse. In clinical practice, this often translates into risk aversive guidance to avoid using the arm. This could lead to a disuse pattern that may increase the likelihood of injury from common activities of daily living. Further, such guidance poses an additional barrier to staying physically active, potentially translating to weight gain, which has been shown to be associated with worse clinical course for women with lymphedema. We hypothesize that a program of slowly progressive strength training with no upper limit on the amount of weight that may be lifted would gradually increase the physiologic capacity of the arm so that common activities represent a decreasing percentage of maximal capacity. Theoretically, this increased capacity should decrease the risk that daily activities put stress on the lymphatic system of the affected side. The Physical Activity and Lymphedema (PAL) Trial is a recently completed randomized controlled exercise intervention trial that recruited 295 breast cancer survivors (141 with lymphedema at study entry, 154 at risk for lymphedema at study entry). The purpose of this report is to provide detail regarding the study design, statistical design, and protocol of the PAL trial.</EA>
<CC>002B12B04; 002B20E02; 002B02A06</CC>
<FD>Exercice physique; Lymphoedème; Essai clinique; Toxicité; Sécurité; Résistance mécanique; Cancer du sein; Homme; Survivant; Méthodologie; Evaluation performance; Analyse statistique; Protocole expérimental</FD>
<FG>Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein</FG>
<ED>Physical exercise; Lymphedema; Clinical trial; Toxicity; Safety; Strength; Breast cancer; Human; Survivor; Methodology; Performance evaluation; Statistical analysis; Experimental protocol</ED>
<EG>Cardiovascular disease; Lymphatic vessel disease; Malignant tumor; Cancer; Mammary gland diseases; Breast disease</EG>
<SD>Ejercicio físico; Linfedema; Ensayo clínico; Toxicidad; Seguridad; Resistencia mecánica; Cáncer del pecho; Hombre; Sobreviviente; Metodología; Evaluación prestación; Análisis estadístico; Protocolo experimental</SD>
<LO>INIST-18357.354000188266940070</LO>
<ID>09-0268266</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000329 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000329 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0268266
   |texte=   Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors

Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri